Moleculin Biotech Inc. (MBRX)
Moleculin Biotech Statistics
Share Statistics
Moleculin Biotech has 14M shares outstanding. The number of shares has increased by 505.68% in one year.
| Shares Outstanding | 14M |
| Shares Change (YoY) | 505.68% |
| Shares Change (QoQ) | 338.76% |
| Owned by Institutions (%) | 17.39% |
| Shares Floating | 13.88M |
| Failed to Deliver (FTD) Shares | 4.94K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 169.87K, so 5.32% of the outstanding shares have been sold short.
| Short Interest | 169.87K |
| Short % of Shares Out | 5.32% |
| Short % of Float | 5.5% |
| Short Ratio (days to cover) | 2.62 |
Valuation Ratios
The PE ratio is -0.27 and the forward PE ratio is -0.31. Moleculin Biotech's PEG ratio is 0.
| PE Ratio | -0.27 |
| Forward PE | -0.31 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Moleculin Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.08.
| Current Ratio | 0.97 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.28M |
| Employee Count | 17 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.77% in the last 52 weeks. The beta is 2.2, so Moleculin Biotech's price volatility has been higher than the market average.
| Beta | 2.2 |
| 52-Week Price Change | -83.77% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 2.28 |
| Relative Strength Index (RSI) | 36.18 |
| Average Volume (20 Days) | 5.8M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -26.64M |
| Net Income | -21.76M |
| EBITDA | -26.52M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -6.32 |
Balance Sheet
The company has 4.28M in cash and 478K in debt, giving a net cash position of 3.8M.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 478K |
| Net Cash | 3.8M |
| Retained Earnings | -153.37M |
| Total Assets | 16.93M |
| Working Capital | -165K |
Cash Flow
In the last 12 months, operating cash flow was -23.86M and capital expenditures -13K, giving a free cash flow of -23.88M.
| Operating Cash Flow | -23.86M |
| Capital Expenditures | -13K |
| Free Cash Flow | -23.88M |
| FCF Per Share | -6.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MBRX is $8, which is 830.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 830.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 22, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Mar 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -17.14 |
| Piotroski F-Score | 0 |